October 25, 2010
In general, treatment guidelines for HCV-HIV co-infection encourage the initiation of HCV therapy at counts well above the 200 CD4+ cell level. The reason for this is that HCV therapy can temporarily reduce CD4+ cell counts, and if these fall too low there is a risk that life-threatening infections could develop.
Researchers in Barcelona and elsewhere in Spain conducted a pilot study to evaluate the safety of HCV therapy in co-infected people with low CD4+ cell counts. Their results are surprising and may incite the initiation of larger studies to explore the issue of HCV therapy in people with low CD4+ cell counts.
Researchers recruited 11 co-infected volunteers, all who had HCV genotype 1 and who were taking anti-HIV therapy. None had hepatitis A or B or any other significant health condition. They were divided into two groups as follows:
All participants received standard treatment for HCV -- interferon and ribavirin adjusted according to body weight.
Preliminary results of 12 weeks of therapy were made available:
Since no serious AIDS-related infections occurred and significant reductions in HCV viral load were seen, at least over the short-term, the Spanish researchers say that larger and longer studies are warranted in co-infected people with low CD4+ cell counts.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|